Reducing risk of severe hypoglycemia - iNPHORM Study
Second-generation basal insulin analogs can be used as first choice in reducing real-world severe hypoglycemia (Baseline Results Of The iNPHORM Study, USA)
This prospective investigation of real-world hypoglycemia risk stratification in the US suggested that clinicians should prioritize second-generation BIs over first-generation BIs, whenever feasible.
Main Takeaway
Finding from the iNPHORM study corroborate that second-generation BI analogs versus first-generation BIs reduce the rate of SH, irrespective of bolus insulin therapy.
Daytime SH and nocturnal SH were comparable in respondents receiving first-generation versus second-generation BIs.
Whenever possible, clinicians should prioritize second-generation BIs over first-generation BIs.
Why This Matters
Previous trials reported that second-generation BIs reduce SH compared to first-generation BIs.
However, owing to the tightly controlled nature of clinical trials, their applicability in real world can be limited.
The population-based iNPHORM study assessed the effect of second-generation versus first-generation BIs on SH frequency in the real-world practice to complement RCT findings.
Key Results
The iNPHORM study cohort comprised US participants (≥18 to ≤90 years) with T1DM and T2DM taking insulin and/or secretagogues for ≥1 year.
Participants were included from a probability-based internet panel: Approximately 68,000 people with diabetes
T1DM: n = 10,000; T2DM: n = 58,000
26,387 panelists initiated screening
Participants who were unable to understand English, currently pregnant or pregnant in the previous year, and currently enrolled in a drug trial were excluded from study.
Overall, 2,339 participants were eligible for the study; of these, 1,694 completed the baseline questionnaire, of whom 569 reported BI use and were included in the sub-analysis (age: 52.33 [SD, 13.82] years; female: 54.5%; T1DM: 21.6%).
Key outcomes: Crude, real-world frequency of SH* among individual taking first-generation or second-generation BIs and quantification of the potential casual effects of second- versus first-generation BIs on SH frequency
Multivariable negative binomial regression was used to isolate the effect of second-generation versus first-generation BIs (+/- bolus insulin) on self-reportedrates of past-year total SH, daytime SH, and nocturnal SH. Confounding variables were identified from a directed acyclic graph.
Approximately 10.0% versus 54.1% and 7.6% versus 28.3% participants reported receiving second-generation versus first-generation BIs with and without bolus insulin, respectively.
Adjusted SH incidence rate ratios in respondents receiving first-generation versus second-generation BIs were as follows:
Total SH: Respondents without bolus insulin = IRR: 2.70, 95% CI: 1.07–6.84; respondents with bolus insulin = IRR: 1.17, 95% CI: 0.552–2.46
Comparable effects were found for daytime and nocturnal SH in respondents receiving first-generation versus second-generation BIs:
Ratzki-Leewing A, Harris S, Black J, Stirling K, Zou G, Ryan BL. Second-generation basal insulin analogues: first-choice in reducing real-world severe hypoglycemia (baseline results of the iNPHORM study, USA). E-poster Presented at Advanced Technologies and Treatments for Diabetes conference 2021.
By clicking on this link, you will be leaving the Campus Sanofi website and going to another, entirely independent website. Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but its own.